Ligand Stock Resumed at Buy by Citi Following XOMA Royalty Acquisition
Citi has resumed its 'buy' rating for Ligand Pharmaceuticals stock, citing the company's recent acquisition of XOMA Royalty as a key factor.
Results for "XOMA Royalty"
4 stories found
XOMA Royalty to Announce Q4 and Full Year 2025 Financial Results
XOMA Royalty is scheduled to report its financial results for the fourth quarter and the full year of 2025 on March 18, 2026.
Ligand Pharmaceuticals to Acquire XOMA Royalty, Raises 2026 Guidance
Ligand Pharmaceuticals announced its plan to acquire XOMA Royalty for $39 per share, simultaneously increasing its 2026 guidance and earnings per share outlook.
Ligand Pharmaceuticals to Acquire XOMA Royalty for $740 Million
Ligand Pharmaceuticals has announced its acquisition of XOMA Royalty in an all-cash deal valued at nearly $740 million, or $39 per share. This strategic move aims to expand Ligand's portfolio.